Company Overview and News
Estimates for Pattern Energy Group Inc. (PEGI - Free Report) have been revised upward in the past 90 days, which reflects analysts’ optimism in the stock. The Zacks Consensus Estimate for 2018 earnings have surged 41.0% to $1.51.
YUM PEGI DTW IDA DTV PEG DTJ LB DTY FE
2018-09-14 seekingalpha - 2
WallStars show positive broker target price upsides. Ten top "safer" high yield dividend Utilities WallStars showed 0.84-78% net gains as of 9/11/18 broker targets plus dividends.
JE PEGI UGI HUNGF NEP TGS BKH SBS JE CZZ PEG HNP BKHU BIP 0902 BEP
WallStars show positive broker target price upsides. NGG, EOCC, ENIC, SBS, CIG, ENIA, SPKE, TGS, ELP, & JE showed top ten per broker targeted 1yr. prices with 56.1% average 9/11/18.
JE PEGI NG SPKE AY JE APU NGGTF PEG SPH TERP NGG
2018-08-29 seekingalpha - 1
38 of 114 Russell 3000 stocks were called "safer" for dividends by showing positive one-year returns and free cash flow yields greater than dividend yields.
PM BGCP GEO SLDA ANH ORC CHMI CMRE GMRE ACRE PEGI KDP DX GLPI BGCA SFL SIR CLNY PEG LVS IVZ
Champion stocks sustain 25+ annual dividend-increases; Contenders show 10-24; Challengers have 5-9. WallStars show >.5% price-target upsides. 46/126 were 'safer' for showing positive annual-returns, and cash-flow yields >dividend-yields 8/24/18.
HEP PM GEO PFG HMLP GLOP PRU SUN BEP PRU PEGI PFK VLP MORN WLKP SIR PRH CVX LAZ PEG WPC PJH
From 7/15/18-8/15/18, Fredrik Arnold dividend "followers" commented on 37 equities and funds. Some comments were bad news, so some rogues mixed in to create a FollowerFavorite/Rogue (FoFa/Ro) list.
CPLP PEGI CATR HMLP CAT O OPRF WLKP DWDP RHHBF CJREF RHHVF GMLP CNQ CJR.B RHHBY PEG QCOM INTC
Pattern Energy Group (PEGI - Free Report) posted second-quarter 2018 operating earnings of 34 cents per share, beating the Zacks Consensus Estimate of 8 cents by a whopping 325.0%. The figure also improved by a large extent from 16 cents reported in the year-ago quarter. The year-over-year improvement in earnings was due to a decline in general and administrative expenses, along with gains from the acquisitions made in 2017 and 2018.
PEGI DTW DTV WEC AT PEG DTJ UCTI DTY UCTT
Chesapeake Utilities Corporation (CPK - Free Report) is set to report second-quarter 2018 results on Aug 9, before the market opens. Last reported quarter, the company delivered a positive earnings surprise of 4.48%, the average trailing-four quarter beat being 0.29%. Let’s see how things are shaping up prior to the announcement. Factors to Consider Chesapeake Utilities expects strong growth in the margin on the back of capital investments worth $947.
AEE OAS PEGI PEG CPK OGE
2018-08-06 seekingalpha - 1
I published my first article on the Brown Bag Portfolio in early August 2017. At that time, I had been investing in the market for a year. I’d already learned several lessons, namely that panic wasn’t a strategy. Actually, it is a strategy, just not a good one, but one that just about any investor has felt at least more than once. I wasn’t an investor at first, I was a trader and I chased, and then I panicked, and then I chased.
ARU PEGI ARCC D DM PEG
We expect PPL Corporation (PPL - Free Report) to beat earnings in second-quarter 2018, before the market opens on Aug 7. The utility delivered positive earnings surprises in all of the last four quarters, the positive average surprise being 9.09% What Does the Quantitative Model Predict? Our proven model shows that PPL Corp is likely to beat estimates this quarter as it possesses the key components.
PEGI PPL PEG QSII AES OGE
Ontario's Ministry of Natural Resources and Forestry is investigating whether construction crews building a major wind-turbine project on the eastern shores of Georgian Bay amidst tinder-dry conditions caused a forest fire that is now devouring more than 5,600 hectares of land.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET